Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.

Combinatorial chemistry & high throughput screening - 1 Jan 2024

Ying Kaijun, Zou Li, Wang Daquan, Wang Rao, Qian Jun

Abstract excerpt

BACKGROUND: Immunotherapy has been a promising treatment in advanced lung cancer. However, only a few patients could benefit from it. Herein, we aimed to explore mutationrelated predictive biomarkers in lung squamous cell carcinoma (LUSC), which could help develop clinical immunotherapy strategies and screen beneficial populations. METHODS: Co-occurrence and mutually exclusive analysis was conducted on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Connectin

Share to KMT2D gene

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37904553
DOI: 10.2174/0113862073246841230922052004

Genes

TP53
TTN
CSMD3
FAM135B
KMT2D
LRP1B
MUC16
NAV3
RYR2
USH2A
ZFHX4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.PMID 37904553Read ↗

Association Between Tumor Mutation Burden (TMB) and immune microenvironment in lung squamous cell carcinomaSemantic proximity Read ↗

Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.Semantic proximity Read ↗

Identification of prognosis value and immune microenvironment features of ceRNAs in NSCLC with distinct gene mutation.Semantic proximity Read ↗

TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patientsSemantic proximity Read ↗

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 ImmunotherapySemantic proximity Read ↗

Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.Semantic proximity Read ↗

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.Semantic proximity Read ↗

Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.Semantic proximity Read ↗

Molecular Profiling reveals Tumor Immune Microenvironment Heterogeneity of Concurrent Lung Adenocarcinoma and Squamous Cell Carcinoma in Multiple Primary Lung CancersSemantic proximity Read ↗

Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.